Jensen MC - Search Results

1

Tumor PD-L1 co-stimulates primary human CD8(+) cytotoxic T cells modified to express a PD1:CD28 chimeric receptor.

Prosser ME, Brown CE, Shami AF, Forman SJ, Jensen MC. Prosser ME, et al. Among authors: jensen mc. Mol Immunol. 2012 Jul;51(3-4):263-72. doi: 10.1016/j.molimm.2012.03.023. Epub 2012 Apr 11. Mol Immunol. 2012. PMID: 22503210

2

CD20 is a molecular target for scFvFc:zeta receptor redirected T cells: implications for cellular immunotherapy of CD20+ malignancy.

Jensen M, Tan G, Forman S, Wu AM, Raubitschek A. Jensen M, et al. Biol Blood Marrow Transplant. 1998;4(2):75-83. doi: 10.1053/bbmt.1998.v4.pm9763110. Biol Blood Marrow Transplant. 1998. PMID: 9763110 Free article.

3

Human T lymphocyte genetic modification with naked DNA.

Jensen MC, Clarke P, Tan G, Wright C, Chung-Chang W, Clark TN, Zhang F, Slovak ML, Wu AM, Forman SJ, Raubitschek A. Jensen MC, et al. Mol Ther. 2000 Jan;1(1):49-55. doi: 10.1006/mthe.1999.0012. Mol Ther. 2000. PMID: 10933911 Free article.

4

T-cell clones can be rendered specific for CD19: toward the selective augmentation of the graft-versus-B-lineage leukemia effect.

Cooper LJ, Topp MS, Serrano LM, Gonzalez S, Chang WC, Naranjo A, Wright C, Popplewell L, Raubitschek A, Forman SJ, Jensen MC. Cooper LJ, et al. Among authors: jensen mc. Blood. 2003 Feb 15;101(4):1637-44. doi: 10.1182/blood-2002-07-1989. Epub 2002 Oct 10. Blood. 2003. PMID: 12393484 Free article.

5

Engineered CD20-specific primary human cytotoxic T lymphocytes for targeting B-cell malignancy.

Jensen MC, Cooper LJ, Wu AM, Forman SJ, Raubitschek A. Jensen MC, et al. Cytotherapy. 2003;5(2):131-8. doi: 10.1080/14653240310001028. Cytotherapy. 2003. PMID: 12745575

6

Cellular immunotherapy for follicular lymphoma using genetically modified CD20-specific CD8+ cytotoxic T lymphocytes.

Wang J, Press OW, Lindgren CG, Greenberg P, Riddell S, Qian X, Laugen C, Raubitschek A, Forman SJ, Jensen MC. Wang J, et al. Among authors: jensen mc. Mol Ther. 2004 Apr;9(4):577-86. doi: 10.1016/j.ymthe.2003.12.011. Mol Ther. 2004. PMID: 15093188 Free article.

7

Genetic engineering of cytolytic T lymphocytes for adoptive T-cell therapy of neuroblastoma.

Gonzalez S, Naranjo A, Serrano LM, Chang WC, Wright CL, Jensen MC. Gonzalez S, et al. Among authors: jensen mc. J Gene Med. 2004 Jun;6(6):704-11. doi: 10.1002/jgm.489. J Gene Med. 2004. PMID: 15170741

8

Enhanced antilymphoma efficacy of CD19-redirected influenza MP1-specific CTLs by cotransfer of T cells modified to present influenza MP1.

Cooper LJ, Al-Kadhimi Z, Serrano LM, Pfeiffer T, Olivares S, Castro A, Chang WC, Gonzalez S, Smith D, Forman SJ, Jensen MC. Cooper LJ, et al. Among authors: jensen mc. Blood. 2005 Feb 15;105(4):1622-31. doi: 10.1182/blood-2004-03-1208. Epub 2004 Oct 26. Blood. 2005. PMID: 15507526 Free article.

9

Specific recognition and killing of glioblastoma multiforme by interleukin 13-zetakine redirected cytolytic T cells.

Kahlon KS, Brown C, Cooper LJ, Raubitschek A, Forman SJ, Jensen MC. Kahlon KS, et al. Among authors: jensen mc. Cancer Res. 2004 Dec 15;64(24):9160-6. doi: 10.1158/0008-5472.CAN-04-0454. Cancer Res. 2004. PMID: 15604287

10

Biophotonic cytotoxicity assay for high-throughput screening of cytolytic killing.

Brown CE, Wright CL, Naranjo A, Vishwanath RP, Chang WC, Olivares S, Wagner JR, Bruins L, Raubitschek A, Cooper LJ, Jensen MC. Brown CE, et al. Among authors: jensen mc. J Immunol Methods. 2005 Feb;297(1-2):39-52. doi: 10.1016/j.jim.2004.11.021. Epub 2005 Jan 22. J Immunol Methods. 2005. PMID: 15777929

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

164 results

Search Page